Comparison of Epizyme Inc. (EPZM) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)

Epizyme Inc. (NASDAQ:EPZM) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Epizyme Inc. 21.70M 44.65 123.63M -1.74 0.00
Pieris Pharmaceuticals Inc. 42.34M 4.25 7.58M -0.13 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents Epizyme Inc. (NASDAQ:EPZM) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Epizyme Inc. -569.72% -58.8% -50.6%
Pieris Pharmaceuticals Inc. -17.90% -18.1% -5.1%

Risk & Volatility

A beta of 3.19 shows that Epizyme Inc. is 219.00% more volatile than Standard & Poor’s 500. Competitively, Pieris Pharmaceuticals Inc.’s 86.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.86 beta.

Liquidity

Epizyme Inc.’s Current Ratio and Quick Ratio are 7.2 and 7.2 respectively. The Current Ratio and Quick Ratio of its competitor Pieris Pharmaceuticals Inc. are 3.6 and 3.6 respectively. Epizyme Inc. therefore has a better chance of paying off short and long-term obligations compared to Pieris Pharmaceuticals Inc.

Analyst Ratings

Epizyme Inc. and Pieris Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Epizyme Inc. 0 1 6 2.86
Pieris Pharmaceuticals Inc. 0 0 0 0.00

The average target price of Epizyme Inc. is $18.86, with potential upside of 54.21%.

Insider & Institutional Ownership

Roughly 93.4% of Epizyme Inc. shares are held by institutional investors while 66.1% of Pieris Pharmaceuticals Inc. are owned by institutional investors. Insiders held 0.2% of Epizyme Inc. shares. Competitively, 0.21% are Pieris Pharmaceuticals Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Epizyme Inc. 3.34% 24.17% 65.67% 8.46% -28.1% 106.01%
Pieris Pharmaceuticals Inc. -0.99% 4.53% -14.04% -45.75% -64.66% 12.78%

For the past year Epizyme Inc. was more bullish than Pieris Pharmaceuticals Inc.

Summary

On 7 of the 11 factors Pieris Pharmaceuticals Inc. beats Epizyme Inc.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Celgene RIVOT Ltd., Genentech Inc., Glaxo Group Limited, and US Oncology Research, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases. It has strategic partnership agreements with Allergan, Inc.; Sanofi Group; Daiichi Sankyo Company Limited; F.Hoffmann- La Roche Ltd. and Hoffmann- La Roche Inc.; ASKA Pharmaceutical Co., Ltd; and Les Laboratoires Servier and Institut de Recherches Internationales. The company also has a research and licensing agreement with Technische Universität München; and a collaboration agreement with AstraZeneca. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.